阿托伐他汀对急性脑梗死患者血清超敏C反应蛋白及白细胞介素－6的影响

Effect of atorvastatin on the level of serum high - sensitivity C - reactive protein and interleukin -6 in patients with acute cerebral infarction

目的探讨阿托伐他汀对急性脑梗死（ACI）患者血清超敏C反应蛋白（hs—CRP）及白细胞介素－6（IL－6）水平以及神经功能的影响。方法将80例ACI患者随机分为阿托伐他汀组（40例）和常规治疗组（40例）。阿托伐他汀组在常规治疗基础上加用阿托伐他汀20mg，每日1次，连续服用4周。检测治疗前后血清h—CRP和IL－6水平，并进行神经功能缺损程度评分（NDS）评定。并以20例健康体检者作为正常对照组。结果ACI患者血清hs—CRP和IL一6水平较正常对照组明显升高（P〈0．05）；治疗后两组血清hs—CRP和IL-6水平均较治疗前明显下降（均P〈0．05），且阿托伐他汀组较常规治疗组下降明显（P〈0．05）；两组NDS评分较治疗前明显下降（均P〈0．05），且阿托伐他汀组较常规治疗组下降明显（P〈0．05）。结论阿托伐他汀能明显降低ACI患者血清hs—CRP和IL-6水平，并有助于ACI患者的神经功能恢复。

Objective To explore the effect of atorvastatin on the level of serum high sensitivity C - reactive protein （ hs - CRP） and interleukin - 6 （ IL - 6） in patients with acute cerebral infarction （ACI）. Methods Eighty patients with ACI were randomly divided into the atorvastatin therapy group （ n = 40） and the conventional therapy group （ n = 40）. At the basic of conventional therapy, the atorvastatin therapy group was treated with atorvastatin 20 mg/d. Both groups were treated for 4 weeks. The levels of serum hs- CRP and IL-6 were measured and the scores of neurological deficit（NDS） were e- valuated before and after treatment. A healthy control group which approximately matched the experimental group included 20 cases. Results The levels of serum hs - CRP and IL - 6 in both two groups after 14 d treatment were significantly lower than those before treatment （all P 〈 0.05） , and the level of ser- um hs- CRP and IL -6 in atorvastatin therapy group was significantly lower than that in conventional therapy group （ P 〈0.0fi）. NDS of both groups after treatment were lower than those before treatment （P 〈 0.05） , and the scores of atorvastatin therapy group were significantly lower than those of conventional therapy group （ P 〈 0.0fi）. Conclusions Atorvastatin can significantly decrease the level of serum hs -CRP and IL- 6, and it can promote the neurological ruction recovery in the patients with ACI.